Breast Cancer Research and Treatment

, Volume 26, Issue 3, pp 237–246 | Cite as

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

  • Carlos A. Encarnación
  • Daniel R. Ciocca
  • William L. McGuire
  • Gary M. Clark
  • Suzanne A. W. Fuqua
  • C. Kent Osborne


Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. An accurate assessment of receptor status in specimens from tamoxifen-resistant patients could help to understand potential mechanisms of resistance and to predict response to second line hormonal therapies. However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading. We measured ER and PgR by both ligand binding (LBA) and immunohistochemical (IHC) assays in 34 tumors from patients on tamoxifen, 30 of whom were displaying resistance to the drug. These tumors were classified into several receptor phenotypes. Eleven patients, 8 of whom were clearly progressing, expressed both receptors while on tamoxifen. ER was significantly less often negative when measured by IHC, suggesting that ER status by LBA was falsely negative in this group due to receptor occupancy by tamoxifen. Six patients had no detectable ER by LBA or IHC but still expressed PgR. The presence of PgR suggests that ER could still be functional, though undetectable, in these tumors, or that PgR is constitutively expressed by them. Finally, 12 patients were ER and PgR-negative by both assays, suggesting hormonal independence as the mechanism for resistance in this group. In a subset of patients with receptor assays both prior to tamoxifen and at the time of progression while taking the drug, we found that most ER-positive tumors converted to an apparent ER-negative status when assayed by LBA, while PgR status frequently remained unchanged. The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer.

Key words

tamoxifen estrogen receptor progesterone receptor ligand binding assay immunohistochemical assay drug resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Buckley M, Goa KL: Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37: 451–490, 1989Google Scholar
  2. 2.
    Jordan VC, Jeng MH, Jiang J, Stella AL: Hormonal strategies for breast cancer: A new focus at the estrogen receptor as therapeutic target. Semin Oncol 19: 299–307, 1992Google Scholar
  3. 3.
    Katzenellenbogen BS: Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83: 1434–1435, 1991Google Scholar
  4. 4.
    Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992Google Scholar
  5. 5.
    Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds), Breast Diseases. Second Edition. JB Lippincott Co, Philadelphia, 1991, pp 301–325Google Scholar
  6. 6.
    Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA III, McGuire WL: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43: 413–416, 1983Google Scholar
  7. 7.
    Namer M, Lalane C, Baulieu E: Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40: 1750–1752, 1980Google Scholar
  8. 8.
    Noguchi S, Miyauchi K, Nishizawa Y, Koyama H: Induction of progesterone receptor with tamoxifen in human breast cancer with special reference of its behavior over time. Cancer 61: 1345–1349, 1988Google Scholar
  9. 9.
    Waseda N, Kato Y, Imura H, Kurata M: Effects of tamoxifen of estrogen and progesterone receptor in human breast cancer. Cancer Res 41: 1984–1988, 1981Google Scholar
  10. 10.
    Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300–304, 1987Google Scholar
  11. 11.
    Kiang DT, Kollander RE, Thomas T, Kennedy BJ: Up regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49: 5312–5316, 1989Google Scholar
  12. 12.
    Bezwoda R, Meyer K: Effect of α-interferon, 17β-estradiol and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF-7 cells. Cancer Res 50: 5387–5391, 1990Google Scholar
  13. 13.
    Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742–1751, 1978Google Scholar
  14. 14.
    Horwitz K, McGuire WL: Estrogen control of progesterone receptors in human breast cancer. J Biol Chem 253: 223–228, 1978Google Scholar
  15. 15.
    Crawford DJ, Cowan S, Fitch R, Smith DC, Leake RE: Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 56: 137–140, 1987Google Scholar
  16. 16.
    Nomura Y, Tashiro H, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 55: 546–551, 1985Google Scholar
  17. 17.
    Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M, Cassey AJ, Neville AM, Coombes RC: Effects of endocrine therapy on steroid receptor content of breast cancer. Br J Cancer 45: 80–85, 1982Google Scholar
  18. 18.
    McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37: 637–639, 1977Google Scholar
  19. 19.
    Powell B, Garola RE, Chamness GC, McGuire WL: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 39: 1678–1682, 1979Google Scholar
  20. 20.
    Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: Flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420–427, 1988Google Scholar
  21. 21.
    Ciocca DR, Bjercke RJ: Immunohistochemical techniques using monoclonal antibodies. In: Langone JJ, Van Vunakis H (eds), Methods in Enzymology, Vol 121. Immunochemical Techniques. Academic Press, Miami, 1986, pp 562–579Google Scholar
  22. 22.
    Elias JM, Marigiotto MD: Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and peroxidase-labeled avidin biotin (LAB) methods. Am J Clin Pathol 92: 62–67, 1989Google Scholar
  23. 23.
    Greene GL, Sobel MB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51–56, 1984Google Scholar
  24. 24.
    Greene GL, Harris K, Bova R, Kinders R, Moore B, Nolan C: Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol 2: 714–726, 1988Google Scholar
  25. 25.
    Press MF, Greene GL: Immunocytochemical localization of estrogen and progesterone receptors. In: De Lellis RA (ed), Advances in Immunohistochemistry. Raven Press, New York, 1988, pp 341–361Google Scholar
  26. 26.
    Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 1992Google Scholar
  27. 27.
    Jensen EV, Block GE, Smith S, Kyser K, DeSombre E: Estrogen receptors and breast carcinoma response to adrenalectomy. Natl Cancer Inst Monogr 34: 55–70, 1971Google Scholar
  28. 28.
    McGuire WL, Carbone PP, Sears ME: Estrogen receptors in human breast cancer. An overview. In: McGuire WL, Carbone PP, Vollmer EP (eds), Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1976, pp 1–7Google Scholar
  29. 29.
    Rose C, Thorpe SM, Anderson KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of tamoxifen in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16–18, 1985Google Scholar
  30. 30.
    Glauber JG, Kiang DT: The changing role of hormonal treatment in advanced breast cancer. Semin Oncol 19: 308–316, 1992Google Scholar
  31. 31.
    Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen resistant tumors from breast cancer patients. J Clin Oncol 10: 304–310, 1992Google Scholar
  32. 32.
    Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990–994, 1992Google Scholar
  33. 33.
    Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization oftrans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477–1482, 1991Google Scholar
  34. 34.
    Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109, 1991Google Scholar
  35. 35.
    Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44: 836–840, 1984Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Carlos A. Encarnación
    • 1
  • Daniel R. Ciocca
    • 2
  • William L. McGuire
    • 1
  • Gary M. Clark
    • 1
  • Suzanne A. W. Fuqua
    • 1
  • C. Kent Osborne
    • 1
  1. 1.Department of Medicine, Division of Medical OncologyUniversity of Texas Health Science Center at San AntionioSan AntonioUSA
  2. 2.Laboratorio de Reproducción y Lactancia (LARLAC)MendozaArgentina

Personalised recommendations